LAPATINIB 250 mg (Hertab) x 30 Tablets

~~$280.00~~ $135.00

Prescription Required

Lapatinib 250 mg (Hertab) is a targeted anticancer medicine used to treat HER2-positive breast cancer, particularly advanced or metastatic disease. It is often used in combination with other anticancer medicines to help slow tumour growth and improve treatment outcomes. Lapatinib works by blocking proteins that promote the growth and spread of cancer cells.

Generic name	Lapatinib
Strength	250 mg
Manufacturer	Hetero Healthcare
Package size	30 Tablets
Used for	HER2-positive breast cancer
Availability	In Stock
Shipping to	USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries.

Enquire via WhatsApp

Uses of LAPATINIB 250 mg

Treats HER2-positive breast cancer
Treats advanced or metastatic breast cancer
Used in combination with other cancer medicines
Helps slow tumour growth
Supports targeted cancer therapy

Benefits

Targets HER2-positive cancer cells
Slows cancer progression
Helps improve treatment outcomes
Reduces tumour growth
Convenient oral therapy

How Does LAPATINIB Work?

Lapatinib is a tyrosine kinase inhibitor (TKI) that blocks the HER2 and EGFR proteins on cancer cells. By preventing these proteins from sending growth signals, it slows the growth, division, and spread of HER2-positive breast cancer cells.

Side Effects

Diarrhoea
Nausea
Vomiting
Skin rash
Fatigue
Loss of appetite
Hand-foot syndrome
Increased liver enzymes

Precautions

Take the medicine exactly as prescribed, preferably on an empty stomach.
Have regular liver function tests during treatment.
Inform your doctor if you have heart disease or liver problems.
Tell your healthcare provider about all medicines and supplements you are taking.
Avoid grapefruit and grapefruit juice during treatment.
Report severe diarrhoea, chest pain, or shortness of breath immediately.
Attend regular follow-up appointments to monitor your response to treatment.

Author

Reviewed By

Dr. Neeru Mehta

Doctor of Medicine (MD) | Professional Interest in Oncology

Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.